AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors
13 April 2021 - 6:00AM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company developing first-in-class antibody product candidates
focused on emerging immune control mechanisms applicable to
inflammation and immuno-oncology indications, today announced the
appointment of Oleg Nodelman to the company’s Board of
Directors.
“Oleg is an experienced biotechnology company builder with deep
insight in the development and financing of novel therapies,” said
Hamza Suria, president and chief executive officer
of AnaptysBio. “We welcome Oleg to our Board of Directors and
look forward to his contributions to AnaptysBio’s capital-efficient
antibody discovery and development business model.”
“AnaptysBio has an impressive antibody development heritage that
has led to the advancement of eight internally-generated novel
therapeutics into clinical development,” commented Mr. Nodelman. “I
look forward to working with the company’s Board and management
team to advance AnaptysBio’s first-in-class wholly-owned antibody
pipeline for inflammatory and immuno-oncology applications.”
About AnaptysBioAnaptysBio is a
clinical-stage biotechnology company developing first-in-class
antibody product candidates focused on emerging immune control
mechanisms applicable to inflammation and immuno-oncology
indications. The Company’s proprietary anti-inflammatory pipeline
includes its anti-IL-36R antibody imsidolimab, previously referred
to as ANB019, for the treatment of rare inflammatory diseases,
including generalized pustular psoriasis, or GPP, EGFRi skin
toxicity, ichthyosis, hidradenitis suppurativa and acne; its
anti-PD-1 agonist program, ANB030, for treatment of certain
autoimmune diseases where immune checkpoint receptors are
insufficiently activated; and its BTLA modulator program, ANB032,
which is broadly applicable to human inflammatory diseases
associated with lymphoid and myeloid immune cell dysregulation.
AnaptysBio’s antibody pipeline has been developed using its
proprietary somatic hypermutation, or SHM platform, which uses in
vitro SHM for antibody discovery and is designed to replicate key
features of the human immune system to overcome the limitations of
competing antibody discovery technologies. AnaptysBio has
also developed multiple therapeutic antibodies in an
immuno-oncology collaboration with GlaxoSmithKline, including an
anti-PD-1 antagonist antibody (dostarlimab GSK4057190A), an
anti-TIM-3 antagonist antibody (cobolimab, GSK4069889A) and an
anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation
collaboration with Bristol-Myers Squibb, including an anti-PD-1
checkpoint agonist antibody (CC-90006) currently in clinical
development.
Contacts:Dennis MulroyAnaptysBio,
Inc.858.732.0201dmulroy@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jul 2023 to Jul 2024